1997
Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter?
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter? Journal Of Urology 1997, 158: 768-771. DOI: 10.1016/s0022-5347(01)64312-x.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageExpectant managementTract recurrenceMedian followupUreteral resectionSpecific survivalNegative marginsBladder tumorsTumor stageUreteral Carcinoma in Situ at Radical Cystectomy
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy. Journal Of Urology 1997, 158: 768-771.. PMID: 9258077, DOI: 10.1097/00005392-199709000-00020.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageUreteral marginsExpectant managementTract recurrenceMedian followupSpecific survivalUreteral resectionNegative marginsBladder tumorsThe indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients
1995
Metastatic breast cancer to the bladder: A case report
Schneidau T, Stroumbakis N, Choudhury M, Eshgi M, Mallouh C. Metastatic breast cancer to the bladder: A case report. International Urology And Nephrology 1995, 27: 297-300. PMID: 7591593, DOI: 10.1007/bf02564765.Peer-Reviewed Original Research